Literature DB >> 24906690

Relationships between KRAS mutation status and baseline radiographic distribution of disease in patients with stage IV colorectal cancer.

Michael H Rosenthal1, Kyung Won Kim, Charles S Fuchs, Jeffrey A Meyerhardt, Nikhil H Ramaiya.   

Abstract

PURPOSE: KRAS oncogene testing is recommended in all patients with metastatic colorectal cancer due to its impact on treatment selection, but we do not know if KRAS genotype affects extent or pattern of metastases. We investigated whether the initial radiographic distribution of disease varies by KRAS genotype in stage IV colorectal cancer.
MATERIALS AND METHODS: This retrospective study of 65 patients with stage IV colorectal cancer was derived from an institutional clinical trials database. Inclusion criteria required KRAS testing and pretreatment CT studies to be available. Disease burden was characterized by two radiologists.
RESULTS: Univariate analysis showed that there was no significant difference in the initial distribution of disease between KRAS mutant and wild type tumors (P > 0.05). Exploratory analyses showed that patients with poorly differentiated histology had a statistically significant increase in hepatic metastases in the presence of KRAS mutations vs. KRAS wild type genotype (median 5.0 vs. 0.5, P = 0.02).
CONCLUSIONS: No overall difference was found in the initial radiographic distribution of disease between KRAS mutant and wild type colorectal cancers. Patients with both poorly differentiated histology and KRAS mutations had more liver metastases in subgroup analyses.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24906690      PMCID: PMC4346357          DOI: 10.1007/s00261-014-0165-2

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  23 in total

Review 1.  Molecular imaging of cancer with positron emission tomography.

Authors:  Sanjiv Sam Gambhir
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

2.  Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data--methods and preliminary results.

Authors:  Olivier Gevaert; Jiajing Xu; Chuong D Hoang; Ann N Leung; Yue Xu; Andrew Quon; Daniel L Rubin; Sandy Napel; Sylvia K Plevritis
Journal:  Radiology       Date:  2012-06-21       Impact factor: 11.105

3.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

Authors:  Jean-Yves Douillard; Kelly S Oliner; Salvatore Siena; Josep Tabernero; Ronald Burkes; Mario Barugel; Yves Humblet; Gyorgy Bodoky; David Cunningham; Jacek Jassem; Fernando Rivera; Ilona Kocákova; Paul Ruff; Maria Błasińska-Morawiec; Martin Šmakal; Jean Luc Canon; Mark Rother; Richard Williams; Alan Rong; Jeffrey Wiezorek; Roger Sidhu; Scott D Patterson
Journal:  N Engl J Med       Date:  2013-09-12       Impact factor: 91.245

Review 4.  Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis.

Authors:  Jian Chen; Yun Ye; Haozhen Sun; Genming Shi
Journal:  Cancer Chemother Pharmacol       Date:  2012-10-23       Impact factor: 3.333

5.  Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies.

Authors:  L Weiss; E Grundmann; J Torhorst; F Hartveit; I Moberg; M Eder; C M Fenoglio-Preiser; J Napier; C H Horne; M J Lopez
Journal:  J Pathol       Date:  1986-11       Impact factor: 7.996

6.  Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver.

Authors:  C C Schimanski; U Linnemann; M R Berger
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

7.  Genetic alterations during colorectal-tumor development.

Authors:  B Vogelstein; E R Fearon; S R Hamilton; S E Kern; A C Preisinger; M Leppert; Y Nakamura; R White; A M Smits; J L Bos
Journal:  N Engl J Med       Date:  1988-09-01       Impact factor: 91.245

8.  Association of K-ras mutations with liver metastases from colorectal carcinoma.

Authors:  Akira Tsunoda; Takeru Iijima; Yuko Tsunoda; Kentaroh Nakao; Michiko Miyaki; Mitsuo Kusano
Journal:  Anticancer Res       Date:  2004 Jul-Aug       Impact factor: 2.480

9.  Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.

Authors:  Christophe Rosty; Joanne P Young; Michael D Walsh; Mark Clendenning; Rhiannon J Walters; Sally Pearson; Erika Pavluk; Belinda Nagler; David Pakenas; Jeremy R Jass; Mark A Jenkins; Aung Ko Win; Melissa C Southey; Susan Parry; John L Hopper; Graham G Giles; Elizabeth Williamson; Dallas R English; Daniel D Buchanan
Journal:  Mod Pathol       Date:  2013-01-25       Impact factor: 7.842

10.  K-ras mutations are correlated to lymph node metastasis and tumor stage, but not to the growth pattern of colon carcinoma.

Authors:  Abdul Mannan; Victoria Hahn-Strömberg
Journal:  APMIS       Date:  2011-12-22       Impact factor: 3.205

View more
  2 in total

Review 1.  Overview of serum and tissue markers in colorectal cancer: a primer for radiologists.

Authors:  Apurva Bonde; Daniel A Smith; Elias Kikano; Jennifer M Yoest; Sree H Tirumani; Nikhil H Ramaiya
Journal:  Abdom Radiol (NY)       Date:  2021-08-20

2.  Multimodality Treatment of a Colorectal Cancer Stage IV Patient with FOLFOX-4, Bevacizumab, Rigvir Oncolytic Virus, and Surgery.

Authors:  Andra Tilgase; Evija Olmane; Jurijs Nazarovs; Linda Brokāne; Romualds Erdmanis; Agnija Rasa; Pēteris Alberts
Journal:  Case Rep Gastroenterol       Date:  2018-08-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.